Status:
COMPLETED
A Clinical Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
Lead Sponsor:
Dow Pharmaceutical Sciences
Conditions:
Acne Vulgaris
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the safety and effectiveness of IDP-107 in treating patients with acne vulgaris.
Eligibility Criteria
Inclusion
- Presence of inflammatory and non-inflammatory lesions
Exclusion
- Dermatological conditions of the face that could interfere with clinical evaluations
- Female subjects who are pregnant, nursing, planning a pregnancy, or become pregnant during the study
Key Trial Info
Start Date :
January 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
366 Patients enrolled
Trial Details
Trial ID
NCT00666900
Start Date
January 1 2008
End Date
September 1 2009
Last Update
February 20 2012
Active Locations (25)
Enter a location and click search to find clinical trials sorted by distance.
1
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States, 71913
2
Dermatology Research of Arkansas, PLLC
Little Rock, Arkansas, United States, 72205
3
RADY Children's Hospital - San Diego
San Diego, California, United States, 92123
4
Clinical Science Institute
Santa Monica, California, United States, 90404